SALE EXTENDED
MarketBeat All Access
Start your 30-day free trial,
then continue your subscription for 50% off.
TODAY ONLY!
Claim Your Discount
×
S&P 500   3,639.66 (-2.80%)
DOW   29,296.79 (-2.11%)
QQQ   269.10 (-3.81%)
AAPL   140.09 (-3.67%)
MSFT   234.24 (-5.09%)
META   133.45 (-4.04%)
GOOGL   98.68 (-2.70%)
AMZN   114.56 (-4.77%)
TSLA   223.07 (-6.32%)
NVDA   120.76 (-8.03%)
NIO   13.76 (-6.84%)
BABA   81.24 (-3.65%)
AMD   58.44 (-13.87%)
T   14.94 (-2.48%)
MU   52.91 (-3.13%)
CGC   2.79 (-25.60%)
F   12.20 (-1.29%)
GE   64.56 (-2.51%)
DIS   97.16 (-2.88%)
AMC   6.53 (-8.29%)
PYPL   90.17 (-4.50%)
PFE   42.32 (-1.79%)
NFLX   224.75 (-6.36%)
S&P 500   3,639.66 (-2.80%)
DOW   29,296.79 (-2.11%)
QQQ   269.10 (-3.81%)
AAPL   140.09 (-3.67%)
MSFT   234.24 (-5.09%)
META   133.45 (-4.04%)
GOOGL   98.68 (-2.70%)
AMZN   114.56 (-4.77%)
TSLA   223.07 (-6.32%)
NVDA   120.76 (-8.03%)
NIO   13.76 (-6.84%)
BABA   81.24 (-3.65%)
AMD   58.44 (-13.87%)
T   14.94 (-2.48%)
MU   52.91 (-3.13%)
CGC   2.79 (-25.60%)
F   12.20 (-1.29%)
GE   64.56 (-2.51%)
DIS   97.16 (-2.88%)
AMC   6.53 (-8.29%)
PYPL   90.17 (-4.50%)
PFE   42.32 (-1.79%)
NFLX   224.75 (-6.36%)
S&P 500   3,639.66 (-2.80%)
DOW   29,296.79 (-2.11%)
QQQ   269.10 (-3.81%)
AAPL   140.09 (-3.67%)
MSFT   234.24 (-5.09%)
META   133.45 (-4.04%)
GOOGL   98.68 (-2.70%)
AMZN   114.56 (-4.77%)
TSLA   223.07 (-6.32%)
NVDA   120.76 (-8.03%)
NIO   13.76 (-6.84%)
BABA   81.24 (-3.65%)
AMD   58.44 (-13.87%)
T   14.94 (-2.48%)
MU   52.91 (-3.13%)
CGC   2.79 (-25.60%)
F   12.20 (-1.29%)
GE   64.56 (-2.51%)
DIS   97.16 (-2.88%)
AMC   6.53 (-8.29%)
PYPL   90.17 (-4.50%)
PFE   42.32 (-1.79%)
NFLX   224.75 (-6.36%)
S&P 500   3,639.66 (-2.80%)
DOW   29,296.79 (-2.11%)
QQQ   269.10 (-3.81%)
AAPL   140.09 (-3.67%)
MSFT   234.24 (-5.09%)
META   133.45 (-4.04%)
GOOGL   98.68 (-2.70%)
AMZN   114.56 (-4.77%)
TSLA   223.07 (-6.32%)
NVDA   120.76 (-8.03%)
NIO   13.76 (-6.84%)
BABA   81.24 (-3.65%)
AMD   58.44 (-13.87%)
T   14.94 (-2.48%)
MU   52.91 (-3.13%)
CGC   2.79 (-25.60%)
F   12.20 (-1.29%)
GE   64.56 (-2.51%)
DIS   97.16 (-2.88%)
AMC   6.53 (-8.29%)
PYPL   90.17 (-4.50%)
PFE   42.32 (-1.79%)
NFLX   224.75 (-6.36%)
NASDAQ:INGN

Inogen - INGN Stock Forecast, Price & News

$22.00
-1.14 (-4.93%)
(As of 10/7/2022 05:12 PM ET)
Add
Compare
Today's Range
$21.78
$22.99
50-Day Range
$22.74
$31.80
52-Week Range
$21.78
$43.00
Volume
168,707 shs
Average Volume
179,477 shs
Market Capitalization
$503.05 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$41.00

Inogen MarketRank™ Forecast

Analyst Rating
Hold
2.25 Rating Score
Upside/​Downside
86.4% Upside
$41.00 Price Target
Short Interest
Healthy
3.30% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.00
Upright™ Environmental Score
News Sentiment
0.31mentions of Inogen in the last 14 days
Based on 6 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.77) to ($1.13) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.25 out of 5 stars

Medical Sector

337th out of 1,072 stocks

Surgical Appliances & Supplies Industry

10th out of 25 stocks

INGN stock logo

About Inogen (NASDAQ:INGN) Stock

Inogen, Inc., a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The company offers Inogen One, a portable device that concentrate the air around the patient to provide a single source of supplemental oxygen; Inogen At Home stationary oxygen concentrators; Inogen Tidal Assist Ventilators, as well as related accessories. The company also rents its products directly to patients. Inogen, Inc. was incorporated in 2001 and is headquartered in Goleta, California.

Receive INGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Inogen and its competitors with MarketBeat's FREE daily newsletter.

INGN Stock News Headlines

3 Reasons to Hold Inogen (INGN) Stock in Your Portfolio
Inogen, Inc. (INGN)
See More Headlines
Receive INGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Inogen and its competitors with MarketBeat's FREE daily newsletter.

INGN Company Calendar

Last Earnings
8/04/2022
Today
10/07/2022
Next Earnings (Estimated)
11/03/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Surgical appliances & supplies
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:INGN
Fax
N/A
Employees
1,021
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$41.00
High Stock Price Forecast
$47.00
Low Stock Price Forecast
$30.00
Forecasted Upside/Downside
+86.4%
Consensus Rating
Hold
Rating Score (0-4)
2.25
Research Coverage
4 Analysts

Profitability

Net Income
$-6,330,000.00
Pretax Margin
-5.19%

Debt

Sales & Book Value

Annual Sales
$358 million
Cash Flow
$0.63 per share
Book Value
$16.29 per share

Miscellaneous

Free Float
22,594,000
Market Cap
$503.05 million
Optionable
Optionable
Beta
1.02

Key Executives

  • Mr. Nabil Shabshab (Age 57)
    CEO, Pres & Director
    Comp: $3.24M
  • Ms. Alison Perry BauerleinMs. Alison Perry Bauerlein (Age 41)
    Co-Founder
    Comp: $621.06k
  • Mr. Bart Sanford (Age 56)
    Exec. VP of Operations
    Comp: $558.22k
  • Dr. Stanislav Glezer M.D. (Age 49)
    MBA, Exec. VP & CTO
    Comp: $628.3k
  • Mr. George J. Parr (Age 51)
    Exec. VP & Chief Commercial Officer
    Comp: $799.95k
  • Ms. Kristin A. Caltrider (Age 54)
    Exec. VP, CFO & Treasurer
  • Ms. Agnes Lee
    Sr. VP of Investor Relations & Strategic Planning
  • Mr. Jason Somer (Age 54)
    Exec. VP, Gen. Counsel & Corp. Sec.
  • Ms. Jennifer Yi Boyer
    Exec. VP & Chief HR Officer
  • Mr. Matthew Pigeon
    Investor Relations Officer













INGN Stock - Frequently Asked Questions

Should I buy or sell Inogen stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Inogen in the last year. There are currently 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" INGN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in INGN, but not buy additional shares or sell existing shares.
View INGN analyst ratings
or view top-rated stocks.

What is Inogen's stock price forecast for 2022?

4 Wall Street research analysts have issued 1-year price targets for Inogen's stock. Their INGN share price forecasts range from $30.00 to $47.00. On average, they predict the company's share price to reach $41.00 in the next twelve months. This suggests a possible upside of 87.6% from the stock's current price.
View analysts price targets for INGN
or view top-rated stocks among Wall Street analysts.

How have INGN shares performed in 2022?

Inogen's stock was trading at $34.00 at the beginning of 2022. Since then, INGN stock has decreased by 35.7% and is now trading at $21.85.
View the best growth stocks for 2022 here
.

When is Inogen's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our INGN earnings forecast
.

How were Inogen's earnings last quarter?

Inogen, Inc. (NASDAQ:INGN) posted its earnings results on Thursday, August, 4th. The medical technology company reported ($0.02) EPS for the quarter, beating analysts' consensus estimates of ($0.40) by $0.38. The medical technology company had revenue of $103.38 million for the quarter, compared to analysts' expectations of $100.64 million. Inogen had a negative trailing twelve-month return on equity of 5.35% and a negative net margin of 8.03%. The firm's quarterly revenue was up 1.8% compared to the same quarter last year. During the same period in the prior year, the company posted $0.22 EPS.

What guidance has Inogen issued on next quarter's earnings?

Inogen issued an update on its third quarter 2022 earnings guidance on Thursday, September, 1st. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $97.00 million-$100.00 million, compared to the consensus revenue estimate of $98.77 million.

What is Scott Wilkinson's approval rating as Inogen's CEO?

70 employees have rated Inogen Chief Executive Officer Scott Wilkinson on Glassdoor.com. Scott Wilkinson has an approval rating of 46% among the company's employees. This puts Scott Wilkinson in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Inogen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Inogen investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), Incyte (INCY), (MDVN) (MDVN), NVIDIA (NVDA), Alibaba Group (BABA), Advanced Micro Devices (AMD), First Solar (FSLR), Intel (INTC) and Netflix (NFLX).

What is Inogen's stock symbol?

Inogen trades on the NASDAQ under the ticker symbol "INGN."

How do I buy shares of Inogen?

Shares of INGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Inogen's stock price today?

One share of INGN stock can currently be purchased for approximately $21.85.

How much money does Inogen make?

Inogen (NASDAQ:INGN) has a market capitalization of $499.71 million and generates $358 million in revenue each year. The medical technology company earns $-6,330,000.00 in net income (profit) each year or ($1.25) on an earnings per share basis.

How many employees does Inogen have?

The company employs 1,021 workers across the globe.

How can I contact Inogen?

Inogen's mailing address is 326 BOLLAY DRIVE, GOLETA CA, 93117. The official website for the company is www.inogen.com. The medical technology company can be reached via phone at (805) 562-0500 or via email at mpigeon@inogen.net.

This page (NASDAQ:INGN) was last updated on 10/7/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access members have access to premium reports, best-in-class portfolio monitoring tools, and our latest stock picks.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies, and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.